The FDA has cleared UpDoc, a prescription software platform that lets patients manage their insulin dosing through a conversational AI, in what the company calls the first cleared software-as-a-medical-device built around a patient-facing large language model.
Withings unveiled StethO Sense at IFA Berlin, an AI feature that analyzes heart and lung sounds recorded through its BeamO device and returns results in seconds, with a public rollout set for October 1, 2026.
Cleveland Clinic became the first health system to test Siemens Healthineers' FDA-cleared AI Rad Companion Prostate MRI in a clinical trial, aiming to confirm it matches radiologists before wider rollout.
A deep-learning model called NYU-DRP outperformed existing tools at forecasting a woman's five-year breast cancer risk by studying her mammograms over multiple years instead of just the latest one.
Apple's updated Health app now folds Apple Watch, iPhone, and lab data into AI-generated health insights, leaning on privacy as its main differentiator against Google's and Samsung's AI wellness coaches.
New California laws require AI chatbot companies to build self-harm crisis protocols, risk assessments, and parental controls for minors, joining a wave of state action following lawsuits over teen chatbot deaths.
MIT researchers used an AI model called CleaveNet to design entirely new peptide sensors that detect cancer-linked enzyme activity through a simple urine test, an early step toward a multiplexed at-home diagnostic that could screen for dozens of cancer types.
Ultrahuman posted $64 million in revenue and its first-ever profit in fiscal 2025, a 5.4x jump that helped it land a $70 million round led by Qualcomm Ventures — part of a smart ring category now growing faster than smartwatches.
A phishing attack on AI utilization-management vendor Xsolis exposed the medical and personal data of 1.4 million patients across eight U.S. health systems, including Mayo Clinic and UW Medicine.
Johnson & Johnson's Ottava surgical robot finally won FDA authorization in July 2026 after more than a decade of delays, entering a soft-tissue robotic surgery market suddenly crowded with new AI-guided rivals.